Constructions (2) Registration of 100 drugs formulas (54 formulas for human medicine and 46 formulas for animals) owned by the seller (3) Registration of special drug formulas, consisting of 12 formulas including

5.8 Manufacture and skincare products, cosmetics, food supplements and medicine used to treat skin diseases segment 9,708 2.2 13,124 3.2 (3,416) (26.0) total 443,248 100.0 417,617 100.0 25,631 6.1 The

gained dividend from RPCL for Baht 150 million and recognized construction income from IRPC-CP Phase 1’s contractor for Baht 66 million, resulting in the increase of the profit. When comparing the net

expenditure of governmental sector and consumer of private sector. Those economic conditions influence the previous Quarter / that the Group gained more revenue from product distribution and service business at

2nd quarter of 2020, the company and its subsidiaries gained the construction income of Baht 41.52 million from one of the subsidiaries whereas in the same quarter of 2019 was Baht 44.36 million showing

32.6 Debt Service Coverage 904.1 4.4 103.9 4.6 Total Debt to Equity 0.2 0.4 0.2 0.4 * calculated by using earnings of current quarter to be estimated for annual earnings ** based on only cost of medicine

operations for 2nd Quarter of 2017 decreased to 71.69%, while it was 74.38% for the 2nd Quarter of 2016. These resulted from the efficiency of medicine and medical supplies cost management, introducing an

personnel to support its expansion such as Cardiac Medicine department and Opthalmology department. Selling Expenses For the 6-month periods of 2015 and 2016 , the Company and its subsidiary incurred selling

Totabl Debt to Equity 0.13 0.25 * based on only cost of medicine & medical supplies

medicine & medical supplies